A study of Coversin for the treatment of bullous pemphigoid in patients who are refractory to oral steroids

Trial Profile

A study of Coversin for the treatment of bullous pemphigoid in patients who are refractory to oral steroids

Planning
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs Coversin (Primary)
  • Indications Bullous pemphigoid
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 27 Apr 2017 New trial record
    • 24 Apr 2017 According to an Akari Therapeutics media release, the company anticipates data from this trial in fourth quarter of 2018.
    • 24 Apr 2017 According to an Akari Therapeutics media release, the company expects to commence this study in first quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top